NCT05788679View on ClinicalTrials.gov

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Myelodysplastic SyndromesAcute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% BlastsMixed Myelodysplastic/Myeloproliferative Disease
Interventions
DRUG

Azacitidine

Azacitidine

OTHER

Donor lymphocytes

Donor lymphocytes in patients without immune suppression

OTHER

Tapering of immune suppression

Tapering of immune suppression in patients who are on immune suppressive drugs

Trial Locations (1)

Unknown

RECRUITING

Department of Hematology, Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Nordic MDS Group

NETWORK

lead

Karolinska University Hospital

OTHER